YU68896A - Jedinjenja hinolina i nihazolina od koristi u terapiji - Google Patents

Jedinjenja hinolina i nihazolina od koristi u terapiji

Info

Publication number
YU68896A
YU68896A YU68896A YU68896A YU68896A YU 68896 A YU68896 A YU 68896A YU 68896 A YU68896 A YU 68896A YU 68896 A YU68896 A YU 68896A YU 68896 A YU68896 A YU 68896A
Authority
YU
Yugoslavia
Prior art keywords
group
ring
optionally substituted
alkoxy
heteroatoms
Prior art date
Application number
YU68896A
Other languages
English (en)
Inventor
John Collis Aalan
Nathan Abraham Fox David
Newman Julie
Original Assignee
Pfizer Research And Development Company N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company N.V./S.A. filed Critical Pfizer Research And Development Company N.V./S.A.
Publication of YU68896A publication Critical patent/YU68896A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak obezbedjuje jedinjenje formule I pri čemu R1 predstavlja C1-4 alkoksi grupu opciono supstituisanu sa jednim ili više atoma fluora; R2 predstavlja H ili C1-6 a alkoksi grupu opciono supstituisanu sa jednim ili više atoma fluora; R3 predstavlja jednu ili više grupa nezavisno izabranih od H, halogena, C1-4 alkoksi i CF3; dalje, R2 i jedna R3 grupa mogu zajedno predstavljati -OCH2-, metilensku grupu vezanu u orto položaju odgovarajućeg fenilnog prstena; R4 predstavlja 4-, 5- ili 6-člani heterociklični prsten koji sadrži 1 ili 2 heteroatoma iz grupe koju čine N, O, i S, pri čemu je prsten opciono spojen sa benzenovim prstenom ili 5- ili 6-člani heterociklični prsten sadrži 1 ili 2 heteroatoma iz grupe koju čine N, O, i S, pri čemu je prsten opciono supstituisan; X predstavlja CH ili N; i L nije prisutno ili predstavlja cikličnu grupu ili otvoreni niz; ili njegovu farmaceutski prihvatljivu so.Jedinjenja formule I su korisna za lečenje inter alia benigne hiperplazije prostate.
YU68896A 1995-12-23 1996-12-20 Jedinjenja hinolina i nihazolina od koristi u terapiji YU68896A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
YU68896A true YU68896A (sh) 1999-07-28

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
YU68896A YU68896A (sh) 1995-12-23 1996-12-20 Jedinjenja hinolina i nihazolina od koristi u terapiji

Country Status (34)

Country Link
US (3) US6103738A (sh)
EP (1) EP0877734B1 (sh)
JP (1) JP3070958B2 (sh)
KR (1) KR19990076693A (sh)
AP (1) AP715A (sh)
AR (1) AR005166A1 (sh)
AT (1) ATE194598T1 (sh)
AU (1) AU708979B2 (sh)
BG (1) BG102559A (sh)
BR (1) BR9612263A (sh)
CA (1) CA2236814C (sh)
CO (1) CO4480106A1 (sh)
CZ (1) CZ197698A3 (sh)
DE (1) DE69609353T2 (sh)
DK (1) DK0877734T3 (sh)
ES (1) ES2151192T3 (sh)
GB (1) GB9526546D0 (sh)
GR (1) GR3034225T3 (sh)
HN (1) HN1996000082A (sh)
HR (1) HRP960616A2 (sh)
HU (1) HUP9903560A3 (sh)
IS (1) IS4731A (sh)
MA (1) MA26414A1 (sh)
NO (1) NO982913L (sh)
NZ (1) NZ325248A (sh)
OA (1) OA10703A (sh)
PL (1) PL327610A1 (sh)
PT (1) PT877734E (sh)
SK (1) SK81698A3 (sh)
TN (1) TNSN96161A1 (sh)
TR (1) TR199801195T2 (sh)
WO (1) WO1997023462A1 (sh)
YU (1) YU68896A (sh)
ZA (1) ZA9610784B (sh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
CN1308324C (zh) 2000-08-31 2007-04-04 弗·哈夫曼-拉罗切有限公司 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物
JP4031363B2 (ja) * 2001-01-02 2008-01-09 エフ．ホフマン−ラ ロシュ アーゲー α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
EP1615909B1 (en) 2003-04-23 2008-07-23 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
ME02970B (me) 2004-06-24 2018-07-20 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
KR20090130051A (ko) 2007-03-14 2009-12-17 엑셀리시스, 인코포레이티드 헤지호그 경로의 억제제
EP2346848B1 (en) 2008-11-14 2013-02-27 F. Hoffmann-La Roche AG Quinazoline derivatives as nk3 receptor antagonists
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
CA2756376A1 (en) * 2009-03-23 2010-09-30 Cipla Limited Process for the preparation of doxazosin and salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PL2473487T3 (pl) 2009-09-03 2017-07-31 Bristol-Myers Squibb Company Chinazoliny jako inhibitory kanałów jonowych potasowych
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
JP6251039B2 (ja) 2011-03-11 2017-12-20 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティドＷ．Ｌ． Ｇｏｒｅ ＆ Ａｓｓｏｃｉａｔｅｓ， Ｉｎｃｏｒｐｏｒａｔｅｄ 固定化された生物学的成分の改良
WO2013043255A1 (en) * 2011-09-21 2013-03-28 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
WO2013130669A1 (en) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
SG11201607973XA (en) 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy

Also Published As

Publication number Publication date
US6642242B2 (en) 2003-11-04
DK0877734T3 (da) 2000-11-20
AU1371997A (en) 1997-07-17
CZ197698A3 (cs) 1999-03-17
AP9600900A0 (en) 1997-01-31
SK81698A3 (en) 2000-04-10
JP3070958B2 (ja) 2000-07-31
US20030220332A1 (en) 2003-11-27
AU708979B2 (en) 1999-08-19
NO982913L (no) 1998-07-30
HUP9903560A3 (en) 2000-07-28
BG102559A (en) 1999-03-31
CA2236814C (en) 2001-09-18
AR005166A1 (es) 1999-04-14
NZ325248A (en) 1999-09-29
PT877734E (pt) 2000-12-29
TNSN96161A1 (fr) 2005-03-15
OA10703A (en) 2002-11-28
HUP9903560A2 (hu) 2000-05-28
MA26414A1 (fr) 2004-12-20
EP0877734A1 (en) 1998-11-18
ES2151192T3 (es) 2000-12-16
HN1996000082A (es) 1997-06-30
CO4480106A1 (es) 1997-07-09
NO982913D0 (no) 1998-06-22
KR19990076693A (ko) 1999-10-15
TR199801195T2 (xx) 1998-10-21
AP715A (en) 1998-12-30
US6103738A (en) 2000-08-15
ATE194598T1 (de) 2000-07-15
JPH11501668A (ja) 1999-02-09
ZA9610784B (en) 1998-06-22
IS4731A (is) 1998-04-29
PL327610A1 (en) 1998-12-21
BR9612263A (pt) 1999-07-13
HRP960616A2 (en) 1998-06-30
EP0877734B1 (en) 2000-07-12
GB9526546D0 (en) 1996-02-28
CA2236814A1 (en) 1997-07-03
DE69609353T2 (de) 2000-12-07
WO1997023462A1 (en) 1997-07-03
DE69609353D1 (de) 2000-08-17
US6750214B2 (en) 2004-06-15
US20020049322A1 (en) 2002-04-25
GR3034225T3 (en) 2000-12-29

Similar Documents

Publication Publication Date Title
YU68896A (sh) Jedinjenja hinolina i nihazolina od koristi u terapiji
YU42296A (sh) Inhibitori ciklične gmp-specifične fosfodiesetaraze
RS50519B (sr) Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona
EA199900531A1 (ru) Хинолиновые и хиназолиновые соединения, применяемые в терапии, особенно при лечении доброкачественной гиперплазии простаты
HRP20000726B1 (en) Quinoline derivatives
DE69427962D1 (de) Biologisch aktive 3-substituierte oxindole verwendbar als anti-angiogenische wirkstoffe
DE69820159D1 (de) Therapeutisch nützliche Chinoline und Quinazoline
DE60006099D1 (de) Chinolinderivate als mek enzym-inhibitoren
RS50893B (sr) Nova dibenzoazulen jedinjenja kao inhibitori faktora nekroze tumora
ATE182889T1 (de) Bicyclische amidinderivate als no-synthetase inhibitoren
ES2190809T3 (es) Compuestos de quinolina y quinazolina utiles en terapia.
YU47219B (sh) Antivirusna tetrahidroimidazo (1,4) benzodiazepin-2-tiona jedinjenja i postupak za njihovo dobijanje
RS51126B (sr) Postupak za pripremanje mezilata piperazin derivata
DE69008542D1 (de) Chinolinderivate, ihre herstellung und verwendung.
ATE268328T1 (de) Neue diazol-derivate und ihre verwendung als serotonergische wirkstoffe
ATE266026T1 (de) Benzofurancarboxamide und deren therapeutische verwendung
YU16196A (sh) Upotreba novih benzohinolin-3-ona i njihovih farmaceutski prihvatljivih soli za proizvodnju leka
EA200400469A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
DE60116855D1 (de) Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität
IL97611A (en) Heterocyclic compounds, their preparation and pharmaceutical compositions containing them